Sales of Novo Nordisk’s diabetes drugs including Ozempic slow sharply | Pharmaceuticals industry

The sales of injectable diabetes drugs, including Novo Nordisk’s Ozempic, slowed down sharply in the midst of the threat of violent competition and the threat of US tariffs, and began to reduce costs and sharpen their commercial focus.

In recent years, the developing sales of GLP-1 diabetes and obesity drugs, the Danish drug producer, which has transformed it into the most valuable company in Europe, has lost $ 95 billion (£ 71.5 billion) since its full-year sales forecast last week.

On Wednesday, Novo Nordisk, blood sugar levels and appetite regulating GLP-1 intestinal hormone, such as ozempic sales, such as the sale of drugs, said last year from 21% to 21%, he said. Sales of obesity drugs, including Wegovy, increased by 56% and 16% increased to 155 billion Danish Kroner (£ 18 billion). Pre -tax profit increased by 24%.

The company has lost its market share for cheaper versions made by US rival Eli Lilly’s Mounjaro and generic pharmaceutical manufacturers. In addition, although the US regulator has recently ended the application, it was also shot by the “merger de in the United States, where pharmacies formed drugs from materials.

Novo Nordisk’s outgoing CEO Lars Fruergaard Jørgensen said that on Thursday, Maziar Mike Dustdar will be delivered to Mazi Mike Dustdar, the company has taken measures to “further sharpen our commercial execution and ensure efficiency in our cost base while continuing to invest in future growth”.

The company is currently waiting for sales growth between 8% and 14% in fixed exchange rates in 2025, and fell sharply in a sharp manner of 13% to 21% of its previous estimate.

Jørgensen added: um I am sure that Novo Nordisk will maximize the important growth opportunities supported by Mike Dustdar with more than 1 billion people living with obesity, including more than 100 million living in the USA, to the maximum level of growth opportunities supported by a strong product portfolio and the future pipeline. ”

The company also announced that it has developed a few kilos of loss of drugs, including those who have recently completed the clinical study of Ara (Phase II) clinical work.

In the US, Novo Nordisk is filed for a class case from investors who claim to mislead with optimistic growth forecasts in the profitable weight loss market.

UBS Analyst Matthew Weston said: “We expect the GLP-1 compounds to stay in the US, which limits cash payment purchase and leaves an uncertain look for Wegovy.

“President Trump’s proposal to repaying GLP-1 obesity in Medicare can provide significant volume increase, but the demands of offering cash sales in US prices most developed nation may significantly reduce the value.”

Derren Nathan, The Head of Equity Research at Hargreaves Lansdown, Said: Valuable Company.